| Joseph D Redle, MD FACC | |
|
95 Arch St, Akron, OH 44304-1437 | |
| (330) 376-7000 | |
| (330) 376-1066 |
| Full Name | Joseph D Redle |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 33 Years |
| Location | 95 Arch St, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073623351 | NPI | - | NPPES |
| 2034686 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 35072562 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Summa Health System | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summa Physicians Inc | 2961303532 | 640 |
News Archive
iCo Therapeutics Inc. - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1 clinical trial of iCo-007, having enrolled all patients in four cohorts of increasing concentration (110ug, 350ug, 700ug, 1000ug), has to date demonstrated a positive safety profile.
A new study from the ABCSG indicates that women suffering from metastasized breast cancer do not benefit from surgery performed prior to drug treatment.
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company's plan to regain compliance with the Exchange's continued listing standards, as submitted by the Company in June.
Results of a clinical trial using transcatheter aortic valve replacement provided a "strong signal" that it is safe for patients with low surgical risk, potentially helping to open the way for broader use of the minimally invasive procedure, also known as TAVR.
According to reports a number of people working for the West Australian Health Department have been suspended because of suspect behaviour.
› Verified 3 days ago
| Entity Name | Summa Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235167719 PECOS PAC ID: 2961303532 Enrollment ID: O20040116000295 |
News Archive
iCo Therapeutics Inc. - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1 clinical trial of iCo-007, having enrolled all patients in four cohorts of increasing concentration (110ug, 350ug, 700ug, 1000ug), has to date demonstrated a positive safety profile.
A new study from the ABCSG indicates that women suffering from metastasized breast cancer do not benefit from surgery performed prior to drug treatment.
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company's plan to regain compliance with the Exchange's continued listing standards, as submitted by the Company in June.
Results of a clinical trial using transcatheter aortic valve replacement provided a "strong signal" that it is safe for patients with low surgical risk, potentially helping to open the way for broader use of the minimally invasive procedure, also known as TAVR.
According to reports a number of people working for the West Australian Health Department have been suspended because of suspect behaviour.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph D Redle, MD FACC 525 E Market St, Po Box 2090, Akron, OH 44304-1619 Ph: (330) 376-7000 | Joseph D Redle, MD FACC 95 Arch St, Akron, OH 44304-1437 Ph: (330) 376-7000 |
News Archive
iCo Therapeutics Inc. - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1 clinical trial of iCo-007, having enrolled all patients in four cohorts of increasing concentration (110ug, 350ug, 700ug, 1000ug), has to date demonstrated a positive safety profile.
A new study from the ABCSG indicates that women suffering from metastasized breast cancer do not benefit from surgery performed prior to drug treatment.
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company's plan to regain compliance with the Exchange's continued listing standards, as submitted by the Company in June.
Results of a clinical trial using transcatheter aortic valve replacement provided a "strong signal" that it is safe for patients with low surgical risk, potentially helping to open the way for broader use of the minimally invasive procedure, also known as TAVR.
According to reports a number of people working for the West Australian Health Department have been suspended because of suspect behaviour.
› Verified 3 days ago
Dr. Michael A Pelini, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St, Ste 300, Akron, OH 44304 Phone: 330-376-7000 Fax: 330-376-1066 | |
David P. Lang, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 4125 Medina Rd, #200c, Akron, OH 44333 Phone: 330-665-8031 Fax: 330-665-8360 | |
Ms. Tiffany Mccann, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3561 | |
Jonathan Buggey, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St Ste 300, Akron, OH 44304 Phone: 724-422-6808 | |
Shamsa Baaj, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Mira Rohit Patel, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 161 N Forge St Ste 198, Akron, OH 44304 Phone: 330-375-3039 | |
Richard J Streck, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, 5th Floor Ambulatory Care Center, Akron, OH 44307 Phone: 330-344-6015 Fax: 330-344-6820 |